These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

236 related articles for article (PubMed ID: 16019562)

  • 21. Mitoxantrone, etoposide, and intermediate-dose cytarabine: an effective and tolerable regimen for the treatment of refractory acute myeloid leukemia.
    Amadori S; Arcese W; Isacchi G; Meloni G; Petti MC; Monarca B; Testi AM; Mandelli F
    J Clin Oncol; 1991 Jul; 9(7):1210-4. PubMed ID: 2045861
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Myeloid sarcoma of the heart: Extramedullary relapse of acute myeloblastic leukemia, presenting with complete heart block and atrial flutter after second allogeneic stem cell transplantation.
    Babaoğlu K; Azizoğlu M; Başar EZ; Zengin E; Usta E; Sarper N
    Echocardiography; 2021 Jun; 38(6):1084-1088. PubMed ID: 34018636
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cardiac myeloid sarcoma: a case report and review of literature.
    Cash T; Becton D; Mian A
    J Pediatr Hematol Oncol; 2011 Oct; 33(7):e330-2. PubMed ID: 21941137
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Isolated central nervous system relapse presenting as myeloid sarcoma of acute myeloid leukemia after allogeneic peripheral blood stem cell transplantation.
    Cho SF; Liu TC; Chang CS
    Ann Hematol; 2013 Jan; 92(1):133-5. PubMed ID: 22878457
    [No Abstract]   [Full Text] [Related]  

  • 25. Refractory disseminated fusariosis by Fusarium verticillioides in a patient with acute myeloid leukaemia relapsed after allogeneic hematopoietic stem cell transplantation: a case report and literature review.
    Fanci R; Pini G; Bartolesi AM; Pecile P
    Rev Iberoam Micol; 2013 Jan; 30(1):51-3. PubMed ID: 22659590
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Timed sequential induction chemotherapy and risk-adapted postremission therapy for acute myelogenous leukemia.
    Kalaycio M; Advani A; Pohlman B; Sekeres M; Tripp B; Rybicki L; Sobecks R
    Am J Hematol; 2008 Nov; 83(11):831-4. PubMed ID: 18756545
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Risk factors for outcome in refractory acute myeloid leukemia patients treated with a combination of fludarabine, cytarabine, and amsacrine followed by a reduced-intensity conditioning and allogeneic stem cell transplantation.
    Pfrepper C; Klink A; Behre G; Schenk T; Franke GN; Jentzsch M; Schwind S; Al-Ali HK; Hochhaus A; Niederwieser D; Sayer HG
    J Cancer Res Clin Oncol; 2016 Jan; 142(1):317-24. PubMed ID: 26424692
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Timed sequential chemotherapy for previously treated patients with acute myeloid leukemia: long-term follow-up of the etoposide, mitoxantrone, and cytarabine-86 trial.
    Archimbaud E; Thomas X; Leblond V; Michallet M; Fenaux P; Cordonnier C; Dreyfus F; Troussard X; Jaubert J; Travade P
    J Clin Oncol; 1995 Jan; 13(1):11-8. PubMed ID: 7799010
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Chemotherapy for acute myeloid leukemias with cytosine arabinoside, daunorubicin, etoposide, and mitoxantrone may cause permanent oligoasthenozoospermia or amenorrhea in middle-aged patients.
    Lemez P; Urbánek V
    Neoplasma; 2005; 52(5):398-401. PubMed ID: 16151584
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Dose-reduced combination of mitoxantrone, etoposide, and cytarabine (miniMEC) for relapsed and refractory acute leukemia.
    Yamamoto C; Ito S; Mashima K; Umino K; Minakata D; Yamasaki R; Kawasaki Y; Sugimoto M; Nakano H; Ashizawa M; Okazuka K; Hatano K; Sato K; Oh I; Fujiwara S; Ohmine K; Suzuki T; Muroi K; Kanda Y
    Leuk Lymphoma; 2016 Nov; 57(11):2541-7. PubMed ID: 26917050
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prospective trial of high-dose chemotherapy followed by infusions of peripheral blood stem cells and dose-escalated donor lymphocytes for relapsed leukemia after allogeneic stem cell transplantation.
    Takami A; Okumura H; Yamazaki H; Kami M; Kim SW; Asakura H; Endo T; Nishio M; Minauchi K; Kumano K; Sugimori N; Mori S; Takemoto Y; Shimadoi S; Ozaki J; Takaue Y; Nakao S
    Int J Hematol; 2005 Dec; 82(5):449-55. PubMed ID: 16533751
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Treatment of recurrence of acute myeloid leukemia in childhood. A retrospective analysis of recurrence in the AML-BFM-83 study].
    Stahnke K; Ritter J; Schellong G; Beck JD; Kabisch H; Lampert F; Creutzig U
    Klin Padiatr; 1992; 204(4):253-7. PubMed ID: 1518261
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Extramedullary relapse presenting as trigeminal neuralgia and diplopia after allogeneic hematopoietic stem cell transplantation.
    Gong J; Li J; Liang H
    Intern Med; 2011; 50(10):1117-9. PubMed ID: 21576839
    [TBL] [Abstract][Full Text] [Related]  

  • 34. FLAG-IDA in the treatment of refractory/relapsed acute myeloid leukemia: single-center experience.
    Pastore D; Specchia G; Carluccio P; Liso A; Mestice A; Rizzi R; Greco G; Buquicchio C; Liso V
    Ann Hematol; 2003 Apr; 82(4):231-5. PubMed ID: 12707726
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Allogeneic Hematopoietic Stem Cell Transplantation as Treatment for Primary Granulocytic Sarcoma of the Breast.
    Li X; Fu J; Xue Y; Yang Y; Wang Y; Zhang C; Zhuo S; Irani F
    Cell Biochem Biophys; 2015 Jul; 72(3):791-4. PubMed ID: 25647745
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Intensification chemotherapy followed by allogenieic and autologous bone marrow transplantation in acute non-lymphoblastic leukemia in children].
    Ortega Aramburu JJ; Olivé Oliveras T; Javier Manchón G; Bastida Vila P; Sánchez C; Giralt López J
    Sangre (Barc); 1991 Feb; 36(1):7-14. PubMed ID: 1853274
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Gastric recurrence of extramedullary granulocytic sarcoma after allogeneic stem cell transplantation for acute myeloid leukemia.
    Choi ER; Ko YH; Kim SJ; Jang JH; Kim K; Kang WK; Jung CW; Kim DH
    J Clin Oncol; 2010 Feb; 28(4):e54-5. PubMed ID: 19917867
    [No Abstract]   [Full Text] [Related]  

  • 38. Therapy of untreated acute myeloid leukemia in the elderly: remission-induction using a non-cytarabine-containing regimen of mitoxantrone plus etoposide.
    Bow EJ; Sutherland JA; Kilpatrick MG; Williams GJ; Clinch JJ; Shore TB; Rubinger M; Schacter BA
    J Clin Oncol; 1996 Apr; 14(4):1345-52. PubMed ID: 8648393
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Single-dose mitoxantrone in combination with continuous infusion intermediate-dose cytarabine plus etoposide for treatment of refractory or early relapsed acute myeloid leukemia.
    Lee SS; Lee JH; Lee JH; Kim DY; Kim SH; Lim SN; Lee YS; Seol M; Ryu SG; Kang YA; Jang S; Park CJ; Chi HS; Yun SC; Lee KH
    Leuk Res; 2009 Apr; 33(4):511-7. PubMed ID: 18819710
    [TBL] [Abstract][Full Text] [Related]  

  • 40. High dose cytarabine and mitoxantrone: an effective induction regimen for high-risk acute myeloid leukemia (AML).
    Larson SM; Campbell NP; Huo D; Artz A; Zhang Y; Gajria D; Green M; Weiner H; Daugherty C; Odenike O; Godley LA; Hyjek E; Gurbuxani S; Thirman M; Sipkins D; Van Besien K; Larson RA; Stock W
    Leuk Lymphoma; 2012 Mar; 53(3):445-50. PubMed ID: 21913806
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.